Adaptive Dengue Antiviral Platform Trial

NCT06551844 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Dengue
Antiviral Drugs

Interventions

DRUG: Molnupiravir 400 mg
DRUG: VIS513 (a monoclonal antibody)
DRUG: Remdesivir 100mg

Sponsor

Oxford University Clinical Research Unit, Vietnam

Collaborators

[object Object]
[object Object]